Around the world over thousands of years, patients have received root-cause holistic treatment for their diseases with personalized
treatment, diet and lifestyle modification recommendations. Read the inspiring true stories of practitioners who heal people and who recovered
from their problems after breast-cancer-recovery treatment at their clinics. Many have been generous to share their knowledge and experience for the benefit
of other holistic experts and patients alike. Many practitioners share their Case Studies and the healing powers of breast-cancer-recovery and related therapies
as they heal people who benefited from our expertise.
Fructose as a carbon source induces an aggressive phenotype in MDA-MB-468 breast tumor cells.
September 2010
/ onclick=”MoreLine(‘8579’, ‘Fructose as a carbon source induces an aggressive phenotype in MDA-MB-468 breast tumor cells.’)”>
…more
/>Int J Oncol. 2010 Sep;37(3):615-22. PMID: 20664930
Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study.
July 2011
INTRODUCTION: Vitamin D has been postulated to be involved in cancer prognosis. Thus far, only two studies reported on its association with recurrence and survival after breast cancer diagnosis yielding inconsistent results. Therefore, the aim of our study was to assess the effect of post-diagnostic serum 25-hydroxyvitamin D [25(OH)D] concentrations on overall survival and distant -free survival.
METHODS:
We conducted a prospective cohort study in Germany including 1,295 incident postmenopausal breast cancer patients aged 50-74 years. Patients were diagnosed between 2002 and 2005 and median follow-up was 5.8 years. Cox proportional hazards models were stratified by age at diagnosis and season of blood collection and adjusted for other prognostic factors. Fractional polynomials were used to assess the true dose-response relation for 25(OH)D.
Results:
Lower concentrations of 25(OH)D were linearly associated with higher risk of death (hazard ratio (HR) = 1.08 per 10 nmol/L decrement; 95% confidence interval (CI), 1.00 to 1.17) and significantly higher risk of distant recurrence (HR = 1.14 per 10 nmol/L decrement; 95%CI, 1.05 to 1.24). Compared with the highest tertile (55 nmol/L), patients within the lowest tertile (35 nmol/L) of 25(OH)D had a HR for overall survival of 1.55 (95%CI, 1.00 to 2.39) and a HR for distant -free survival of 2.09 (95%CI, 1.29 to 3.41). In addition, the association with overall survival was found to be statistically significant only for 25(OH)D levels of blood samples collected before start of chemotherapy but not for that of samples taken after start of chemotherapy (P for interaction = 0.06). CONCLUSIONS: In conclusion, lower serum 25(OH)D concentrations may be associated with poorer overall survival and distant -free survival in postmenopausal breast cancer patients.
/ onclick=”MoreLine(‘7428’, ‘Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study.’)”>
…more
/>Breast Cancer Res. 2011 Jul 26 ;13(4):R74. Epub 2011 Jul 26. PMID: 21791049 [